Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Ovid Therapeutics Inc's Business Segments
Ovid Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2025
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 0
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2025
- Reportable100%
Revenue by Reportable Segment - Q1 FY2025
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 0 | 100% |
Description of Ovid Therapeutics Inc
Ovid Therapeutics Inc. is a biopharmaceutical company that was founded in 2014 by a team of experienced industry leaders and scientists with the goal of developing treatments for rare neurological diseases. The company is headquartered in New York, NY, and is publicly traded on the NASDAQ under the symbol OVID.
The focus of Ovid Therapeutics is on developing innovative therapeutics for patients with rare neurological disorders, including developmental and epileptic encephalopathies (DEEs) and Angelman syndrome. These disorders are caused by genetic mutations that disrupt proper brain function and often lead to severe intellectual disability and other developmental delays.
Ovid Therapeutics' lead drug candidate, OV101, is a highly selective small molecule that is being developed to treat both Angelman syndrome and Fragile X syndrome. These conditions are caused by a deficiency in the inhibitory neurotransmitter GABA, which OV101 is designed to enhance. OV101 is currently in clinical trials, with Phase 3 studies ongoing in Angelman syndrome and Phase 2 trials in Fragile X syndrome.
In addition to OV101, Ovid Therapeutics is developing several other drug candidates, including OV935, a highly selective dual inhibitor of enzymes that regulate the production of neurotransmitters glutamate and GABA. OV935 is being developed as a potential treatment for both DEEs and epileptic spasms.
Ovid Therapeutics has formed partnerships with several leading academic and research institutions to advance its drug development programs. The company has also received funding from several venture capital firms.
Overall, Ovid Therapeutics is a leading biopharmaceutical company focused on developing innovative therapeutics for patients with rare neurological disorders. With a strong pipeline of drug candidates and a highly experienced management team, Ovid is well-positioned to make a meaningful impact in the lives of patients and families affected by these devastating conditions.
The focus of Ovid Therapeutics is on developing innovative therapeutics for patients with rare neurological disorders, including developmental and epileptic encephalopathies (DEEs) and Angelman syndrome. These disorders are caused by genetic mutations that disrupt proper brain function and often lead to severe intellectual disability and other developmental delays.
Ovid Therapeutics' lead drug candidate, OV101, is a highly selective small molecule that is being developed to treat both Angelman syndrome and Fragile X syndrome. These conditions are caused by a deficiency in the inhibitory neurotransmitter GABA, which OV101 is designed to enhance. OV101 is currently in clinical trials, with Phase 3 studies ongoing in Angelman syndrome and Phase 2 trials in Fragile X syndrome.
In addition to OV101, Ovid Therapeutics is developing several other drug candidates, including OV935, a highly selective dual inhibitor of enzymes that regulate the production of neurotransmitters glutamate and GABA. OV935 is being developed as a potential treatment for both DEEs and epileptic spasms.
Ovid Therapeutics has formed partnerships with several leading academic and research institutions to advance its drug development programs. The company has also received funding from several venture capital firms.
Overall, Ovid Therapeutics is a leading biopharmaceutical company focused on developing innovative therapeutics for patients with rare neurological disorders. With a strong pipeline of drug candidates and a highly experienced management team, Ovid is well-positioned to make a meaningful impact in the lives of patients and families affected by these devastating conditions.
Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to the development of innovative medical treatments for rare neurological diseases. The company’s intricate focus on this area reflects its commitment to improving the lives of patients affected by these challenging conditions through a comprehensive range of segments, products, and support services.
Segments:
1. Drug Development:
Ovid Therapeutics operates primarily in drug development, with a keen focus on formulating and advancing treatments aimed at specific rare neurological disorders. The company has an impressive pipeline addressing conditions such as:
- Angelman Syndrome: A genetic disorder leading to severe developmental disabilities and seizures.
- Fragile X Syndrome: The most common inherited cause of intellectual disability and a significant source of developmental challenges.
- CDKL5 Deficiency Disorder: A rare genetic condition characterized by severe seizures and significant developmental delays.
Ovid’s portfolio includes several promising compounds:
- OV101 (gaboxadol)
- OV329
- OV882
2. Research and Development:
Ovid Therapeutics places a strong emphasis on research and development, investing substantial resources in innovative approaches to treat rare neurological diseases. Their R&D initiatives encompass:
- Exploration of novel drug targets.
- Development of new therapeutic classes and modalities.
- Collaborations with academic and research institutions, leveraging external expertise and knowledge.
Products:
1. OV101 (Gaboxadol):
- Mechanism: OV101 is a small molecule designed to act as a GABA-A receptor modulator. By enhancing the inhibitory activity in the brain, OV101 aims to address the neurophysiological challenges associated with Angelman syndrome.
- Status: Currently in clinical development stages, focusing on its safety, efficacy, and impact on seizure reduction and developmental improvements in affected patients.
2. OV329:
- Mechanism: This small molecule therapy is specifically targeting the mGluR5 receptor, which plays a critical role in modulating glutamatergic signaling in the brain. This pathway is essential for regulating synaptic plasticity and overall neurotransmission.
- Target Indication: Primarily under development for use in treating Fragile X syndrome, supported by preclinical findings and ongoing clinical trials.
3. OV882:
- Mechanism: OV882 targets the mitogen-activated protein kinase (MAPK) pathway, which is crucial for several cellular processes, including neuronal signaling and growth.
- Target Indication: Focused on CDKL5 deficiency disorder, this compound aims to ameliorate seizure activity and enhance developmental trajectories for children affected by the condition.
Services:
1. Clinical Trials:
Ovid Therapeutics conducts rigorous clinical trials aimed at assessing the safety and efficacy of their drug candidates. The company collaborates with leading academic institutions and clinical research organizations (CROs) to design, execute, and analyze clinical studies, ensuring that results are both scientifically rigorous and relevant to patient needs.
2. Patient Support Programs:
Ovid Therapeutics is committed to supporting patients and families navigating the challenges of rare neurological diseases. Their Patient Support Programs offer a variety of resources, including:
- Educational materials that help patients understand their conditions and treatment options.
- Financial assistance programs designed to alleviate the burden of treatment costs.
- Access to ongoing clinical trials, allowing patients to participate in cutting-edge research while potentially receiving new therapies.
3. Scientific Collaboration:
The company actively fosters collaborations with prominent academic institutions and research organizations. These partnerships aim to enhance understanding of rare neurological diseases, develop new therapeutic strategies, and ultimately improve patient outcomes. Through collective efforts, Ovid seeks to bridge the gap between laboratory breakthroughs and practical treatment solutions.
Conclusion:
Ovid Therapeutics Inc. stands out as a pioneering entity in the realm of biopharmaceuticals with a dedicated approach to addressing rare neurological diseases. Their robust pipeline of drug candidates, commitment to research and development, and dedication to patient support form the backbone of their operations as they strive to transform the landscape of treatment options available for these disorders.
Segments:
1. Drug Development:
Ovid Therapeutics operates primarily in drug development, with a keen focus on formulating and advancing treatments aimed at specific rare neurological disorders. The company has an impressive pipeline addressing conditions such as:
- Angelman Syndrome: A genetic disorder leading to severe developmental disabilities and seizures.
- Fragile X Syndrome: The most common inherited cause of intellectual disability and a significant source of developmental challenges.
- CDKL5 Deficiency Disorder: A rare genetic condition characterized by severe seizures and significant developmental delays.
Ovid’s portfolio includes several promising compounds:
- OV101 (gaboxadol)
- OV329
- OV882
2. Research and Development:
Ovid Therapeutics places a strong emphasis on research and development, investing substantial resources in innovative approaches to treat rare neurological diseases. Their R&D initiatives encompass:
- Exploration of novel drug targets.
- Development of new therapeutic classes and modalities.
- Collaborations with academic and research institutions, leveraging external expertise and knowledge.
Products:
1. OV101 (Gaboxadol):
- Mechanism: OV101 is a small molecule designed to act as a GABA-A receptor modulator. By enhancing the inhibitory activity in the brain, OV101 aims to address the neurophysiological challenges associated with Angelman syndrome.
- Status: Currently in clinical development stages, focusing on its safety, efficacy, and impact on seizure reduction and developmental improvements in affected patients.
2. OV329:
- Mechanism: This small molecule therapy is specifically targeting the mGluR5 receptor, which plays a critical role in modulating glutamatergic signaling in the brain. This pathway is essential for regulating synaptic plasticity and overall neurotransmission.
- Target Indication: Primarily under development for use in treating Fragile X syndrome, supported by preclinical findings and ongoing clinical trials.
3. OV882:
- Mechanism: OV882 targets the mitogen-activated protein kinase (MAPK) pathway, which is crucial for several cellular processes, including neuronal signaling and growth.
- Target Indication: Focused on CDKL5 deficiency disorder, this compound aims to ameliorate seizure activity and enhance developmental trajectories for children affected by the condition.
Services:
1. Clinical Trials:
Ovid Therapeutics conducts rigorous clinical trials aimed at assessing the safety and efficacy of their drug candidates. The company collaborates with leading academic institutions and clinical research organizations (CROs) to design, execute, and analyze clinical studies, ensuring that results are both scientifically rigorous and relevant to patient needs.
2. Patient Support Programs:
Ovid Therapeutics is committed to supporting patients and families navigating the challenges of rare neurological diseases. Their Patient Support Programs offer a variety of resources, including:
- Educational materials that help patients understand their conditions and treatment options.
- Financial assistance programs designed to alleviate the burden of treatment costs.
- Access to ongoing clinical trials, allowing patients to participate in cutting-edge research while potentially receiving new therapies.
3. Scientific Collaboration:
The company actively fosters collaborations with prominent academic institutions and research organizations. These partnerships aim to enhance understanding of rare neurological diseases, develop new therapeutic strategies, and ultimately improve patient outcomes. Through collective efforts, Ovid seeks to bridge the gap between laboratory breakthroughs and practical treatment solutions.
Conclusion:
Ovid Therapeutics Inc. stands out as a pioneering entity in the realm of biopharmaceuticals with a dedicated approach to addressing rare neurological diseases. Their robust pipeline of drug candidates, commitment to research and development, and dedication to patient support form the backbone of their operations as they strive to transform the landscape of treatment options available for these disorders.